USFDA asks Philips Respironics to notify patients about ventilator recall

Written by MD Bureau Published On 2022-03-12T10:17:11+05:30 | Updated On 12 March 2022 10:17 AM IST

USFDA asks Philips Respironics to notify patients about ventilator recall

"Taking this action today enables the FDA to mandate that Philips Respironics improve its communication about the recall and the serious risk posed by the foam used in the recalled products with patients," the regulator added.

New Delhi: The U.S. Food and Drug Administration (FDA) asked Dutch medical equipment maker Philips Respironics on Thursday to notify patients about the company's recall of certain ventilators and other breathing assistance machines in June last year.

FDA said in a statement that it had determined the order necessary, citing the risk of harm posed by the recalled products.

Read Also - Philips ventilator recall troubles deepen as USFDA finds new issues

"Taking this action today enables the FDA to mandate that Philips Respironics improve its communication about the recall and the serious risk posed by the foam used in the recalled products with patients," the regulator added.

The company said in a statement it would be working with its durable medical equipment (DME) customers to allow the company to directly contact those patients and other end-users that may not yet have received notice of the recall.

Philips Respironics had recalled some breathing devices and ventilators in June last year because of a foam part that might degrade and become toxic, potentially causing cancer.

The health regulator has also recommended the company to provide monthly updates to device users that include information on expected time for replacement and current rate of replacement of recalled devices.

Philips invasive and noninvasive ventilators support the needs of the patient and care providers from hospital through the home. Our solutions are designed to deliver the highest possible clinical and patient experience. The final goal of our partnership is to help care providers and health systems as they navigate complex and changing patient conditions and care settings when treating respiratory insufficiency.

Philips RespironicsUSFDAventilator recall

Source : Reuters

MD Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.